Ibiglustat (L-Malic acid)

Research use only, not for human use.

Ibiglustat (L-Malic acid) is a selective, brain-penetrant, and allosteric inhibitor of glucosylceramide synthase.

Ibiglustat (L-Malic acid) is a selective, brain-penetrant, and allosteric inhibitor of glucosylceramide synthase. Ibiglustat (L-Malic acid) can be used in studies about PD Parkinson’s disease, SRT in Fabry’s and Gaucher’s.(In Vitro):Ibiglustat (L-Malic acid) (1 μM) treated Fabry disease cells are close to the physiological level in untreated WT cells in GL-3 levels. Ibiglustat (L-Malic acid) prevents additional GL-3 accumulation and ameliorates the abundant GL-3 levels in FD cardiomyocytes.

Ibiglustat (SAR402671) (1 μM, 15 days) L-Malic acid treated Fabry disease (FD) cells are close to the physiological level in untreated WT cells in GL-3 levels, suggesting that Ibiglustat L-Malic acid can prevent additional GL-3 accumulation and could serve to ameliorate the abundant levels of this sphingolipid in FD cardiomyocytes.

——

Ibiglustat L-Malic acid | Venglustat (L-Malic acid) | SAR402671 (L-Malic acid) | GZ402671 (L-Malic acid)

Metabolic Enzyme/Protease

Transferase

tubulin polymerization

——

——

1629063-78-0

523.57

C24H30FN3O7S

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (191.00 mM)

[C@H](CC(O)=O)(C(O)=O)O.C(NC(O[C@H]1C2CCN(C1)CC2)=O)(C)(C)C=3N=C(SC3)C4=CC=C(F)C=C4

——

(-20℃)

With Ice Pack

≥ 2 years